Treprostinil for pulmonary disease, chronic obstructive

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 6 Nov 2026: Trial registered, NCT07923526

The trials

NCT07923526: An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)

State
Not started
Phase
Phase 2 and Phase 3
People
400 planned
Started
Mar 2027
Primary completion
Sep 2034
Arms
treprostinil SMI
Results
None posted
  1. 6 Nov 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Trial registered

About the treatment

Also known as Remodulin, Rumodolin, Tyvaso, Uniprost, preservative-free parenteral treprostinil, treprostinil SMI (treprostinil inhalation spray).

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.